| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5616599 | COSETTE | Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use |
Apr, 2016
(8 years ago) | |
|
US5616599 (Pediatric) | COSETTE | Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use |
Oct, 2016
(7 years ago) | |
Tribenzor is owned by Cosette.
Tribenzor contains Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil.
Tribenzor has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Tribenzor are:
- US5616599
- US5616599*PED
Tribenzor was authorised for market use on 23 July, 2010.
Tribenzor is available in tablet;oral dosage forms.
Tribenzor can be used as treatment of hypertension.
The generics of Tribenzor are possible to be released after 25 October, 2016.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Jul 23, 2013 |
Drugs and Companies using AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL ingredient
Market Authorisation Date: 23 July, 2010
Treatment: Treatment of hypertension
Dosage: TABLET;ORAL
More Information on Dosage
TRIBENZOR family patents
